http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Jin Soo,Park, Ga Young,Choi, Han Gyul,Kim, Seong Joung,Kim, June Hyun,park, Min Cheol,Kim, Yun Kyung,Han, Sang Yong,Jo, Eun Heui Korean AcupunctureMoxibustion Medicine Society 2017 대한침구의학회지 Vol.21 No.4
Objectives : The purpose of this study was to evaluate the effects of water extracts of Eucommiae cortex (EC), Psoraleae semen (PS), and their combination on receptor activator of nuclear factor-kappa-B ligand (RANKL)-induced osteoclast differentiation. Methods : We assayed the protein expression levels of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), c-Fos, mitogen-activated protein kinases (MAPKs), and ${\beta}-actin$ in cell lysates using western blotting. Similarly, mRNA expression levels of NFATc1, c-Fos, tartrateresistant acid phosphate (TRAP), and glyceraldehyde-3-phosphate dehydrogenase, spermatogeni (GAPDHS) from bone marrow macrophages (BMMs) were analyzed using reverse transcription-polymerase chain reaction (RT-PCR). Furthermore, we determined the anti-osteoporotic effects of the water extracts of EC, PS, and their combination in a lipopolysaccharide (LPS)-induced bone-loss mouse model. Results : The in vitro data revealed showed that the combination of EC and PS extract showed a more remarkable inhibition of osteoclast differentiation than each herb did alone. The combination downregulated the induction of c-Fos, NFATc1, and TRAP by suppressing the phosphorylation of p38 and c-Jun N-terminal kinases (JNKs) and inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells ($NF-{\kappa}B$). Lastly, the in vivo data showed that PS reduced the LPS-induced bone erosion. Conclusion : The result of this study suggests that EC and PS could be potential therapeutic agents for bone loss diseases such as osteoporosis.
Kim, Young Jin,Cho, Yang Sun,Park, Ga Young,Choi, Ahnryul,Youn, Su Hyun,Sim, Taeyong,Oh, Seung Eel,Yang, Heegoo,Park, Hyunjoon,Lee, Dongjune,Lee, Dae-Weon,Mun, Joung Hwan Korean Society for Precision Engineering 2013 International Journal of Precision Engineering and Vol.14 No.7
Permanent facial nerve damage is one of the most critical complications that can occur during otologic and neurosurgical procedures. As a result, facial nerve monitoring equipment is now used in most of otologic surgeries. The monitoring devices used for this purpose usually evaluate the activity of facial muscle in response to stimulation to the facial nerve. For these purposes, electromyography and the train-of-four (TOF) method is commonly used clinically, but these approaches have an important limitation: this qualitative method only depends on visual information of finger movement. Thus, in this study, a new factor that can be used to quantitatively the stage of muscle relaxation at the facial nerve was developed based on the degree of muscle relaxation and electro-stimulation. Ketamine intravenous anesthesia and isoflurane inhalation anesthesia was given to 13 rabbits. A 28 G unipolar needle-electrode was inserted at an exposed facial nerve, and stimulated (0.1 mA - 5.0 mA) with an electrical stimulator. Also, the degree of muscle relaxation based electromyographic signal acquisition was performed while increasing the dose of neuromuscular blockades. After data noise reduction and normalization, the collected EMG signals were divided into 33 variables, and a new evaluation factor was developed using statistical methods based on multiple linear regression models and principal component analysis. A new evaluation factor was identified that can be used to quantitatively estimate each phase in muscle relation. The evaluating factors that were calculated in accordance with the electrical simulation resulted in improved results (r=0.96) when compared to the existing assessment methods. (T1 ratio r=0.72; T4/T1 ration r=0.52).
아토피피부염 환자에서 국소 tacrolimus 0.1%에 대한 약물정보지 제공의 효과 및 국소 tacrolimus 0.1% 효능과 환자의 순응도 평가
한지수 ( Ji Su Han ),이우진 ( Woo Jin Lee ),고주연 ( Joo Yeon Ko ),김정수 ( Joung Soo Kim ),김상석 ( Sang Seok Kim ),서수홍 ( Soo Hong Seo ),유박린 ( Bark Lynn Lew ),이가영 ( Ga Young Lee ),이주희 ( Ju Hee Lee ),박창욱 ( Chang Ook 대한소아알레르기호흡기학회 1991 소아알레르기 및 호흡기학회지 Vol.1 No.3
Purpose: Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients. Methods: We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient’s global assessment (PGA), and investigator’s global assessment (IGA). Results: Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor. Conclusion: Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance. (Allergy Asthma Respir Dis 2013;1:221-226)
아토피피부염 환자에서 국소 tacrolimus 0.1%에 대한 약물정보지 제공의 효과 및 국소 tacrolimus 0.1% 효능과 환자의 순응도 평가
한지수 ( Ji Su Han ),이우진 ( Woo Jin Lee ),고주연 ( Joo Yeon Ko ),김정수 ( Joung Soo Kim ),김상석 ( Sang Seok Kim ),서수홍 ( Soo Hong Seo ),유박린 ( Bark Lynn Lew ),이가영 ( Ga Young Lee ),이주희 ( Ju Hee Lee ),박창욱 ( Chang Ook 대한소아알레르기호흡기학회 2013 Allergy Asthma & Respiratory Disease Vol.1 No.3
Purpose: Topical calcineurin inhibitor is recently developed topical immunomodulator, and preliminary studies showed its effectiveness in the treatment of atopic dermatitis (AD). However, some side effects including transient irritation can influence the patient compliance. So, there are some needs to improve the patient compliance. The purpose of this study was to evaluate the efficacy, safety and patient compliance with using topical tacrolimus 0.1% to treat AD when the correct information about topical tacrolimus are properly given to patients. Methods: We examined the medical recordings, clinical severity scoring of total 194 AD patients at 9 general hospitals in Seoul, Korea from September 2010 to August 2011. We offered an infosheet of topical tacrolimus 0.1% and the patients applied it twice a day for 2 weeks. And we measured the efficacy of the topical tacrolimus 0.1% with SCORing atopic dermatitis (SCORAD) index, patient’s global assessment (PGA), and investigator’s global assessment (IGA). Results: Topical tacrolimus 0.1% effectively controlled AD with a reduction of the SCORAD index from baseline 31.9 to 20.2 at 2 weeks of application. In IGA results showed 98% got improvement and in PGA, results showed 96% got improvement after treatment. Although 42.3% of the patients complained of adverse effects, these were all transient. The effect of information on topical tacrolimus 0.1% showed 34% patients could predict the side effect, 35% patients could feel safety to use, and 18% patients experienced side effect but could maintain topical calcineurin inhibitor. Conclusion: Topical tacrolimus 0.1% may be an effective treatment modality for AD when patients show good compliance for applying the ointment. And properly given, the correct information may increase the patient compliance. (Allergy Asthma Respir Dis 2013;1:221-226)
한방병원에 내원한 암환자 52명에 대한 NK cell Activity 특성 분석
이가영,김민지,정진용,유주영,조정효,손창규,이남헌,Lee, Ga-young,Kim, Min-ji,Joung, Jin-yong,Ryu, Ju-young,Cho, Jung-hyo,Son, Chang-gue,Lee, Nam-hun 대한한방내과학회 2018 大韓韓方內科學會誌 Vol.39 No.4
Objectives: This study was aimed to analyze the correlation of clinical characteristics of cancer patients treated with Korean Medicine and their natural killer cell activity (NKA). Methods: The medical records of 52 cancer patients who conducted NKA test at Cheonan Korean Medicine Hospital of Daejeon University from March 2016 to May 2018 were reviewed. NKA was determined at Seegene Medical institute using NK Vue Gold(R) kit, evaluating activated $IFN-{\gamma}$ by enzyme immunoassay after incubation of whole blood. Careful investigations were conducted by categorizing the patients by their sex, origin, stage, ECOG scale, and conventional treatment type. We used data from the medical records and statistical analysis using SPSS 25.0 V. Results: The average NKA of all patients was $623.1{\pm}722.0pg/mL$. The NKA value was higher for females than for males. No correlation was evident between age and NKA, but patients aged over 70 years had the lowest NKA average result. Stage III and IV patients showed clearly lower NKA values when compared to stage I and II patients. NKA and ECOG scale values showed no evident relationship. Conclusions: This study presented the characteristics of NKA in cancer patients treated with Korean medicine. The NKA result differed by gender and stage. Based on these findings, further study is needed regarding the clinical meaning of NKA.
이트라코나졸(itraconazole)액의 첨가물에 의해 발생한 지연형 두드러기 및 혈관부종 1예
김수영 ( Soo Young Kim ),최길순 ( Gil Soon Choi ),김희규 ( Hee Kyoo Kim ),김제훈 ( Je Hun Kim ),김철수 ( Cheol Su Kim ),양정욱 ( Joung Wook Yang ),유가인 ( Ga In You ),이진영 ( Jin Young Lee ) 대한천식알레르기학회(구 대한알레르기학회) 2014 Allergy Asthma & Respiratory Disease Vol.2 No.2
Itraconazole, new triazole agent with a broader antifungal spectrum than fluconazole, has been prescribed widely in the treatment and prophylaxis for fungal infection. Itaconazole has been reported to have gastrointestinal disturbance (4%) and headache (1%) as its most common side-effects. However, allergic reactions caused by this drug are rare. A 53 year-old woman with myelodysplastic syndrome received prophylactic antibiotic therapy including itraconazole solution before chemotherapy. She complained of hive on the face with angioedema at 6 hours after taking them. The symptoms were more aggravated on the next day and reversed by stopping itraconazole solution and injection of antihistamine and steroids. Skin prick tests with itraconazole solution, itraconazole tablet, and ketoconazole showed all the negative responses. The oral challenge test with itraconazole solution was performed and resulted in urticaria and angioedema 6 hours later. Next, the oral challenge test with intraconazole tablet was performed and showed negative response. The patient was finally diagnosed as adverse reaction by additives contained intraconazole solution. We report, a case of delayed onset urticaria and angioedema caused by components of itraconazole solution. (Allergy Asthma Respir Dis 2014;2:138-141)